Expanding the youth opioid recovery support (YORS) intervention for moud adherence to adolescents with OUD
Active Project Grant Awarded Last action
- Award ID
- R34DA062260
- Recipient
-
Maryland Treatment Centers, Inc. UEI F5JVNKERKNA5
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,153,350
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 71% complete
- Place of performance
- Baltimore, MD 21229, USA
Award details come from USAspending.gov.
Description
- Abstract
- Abstract adolescents with OUD are a critical but underserved population. Despite rising rates of fatal opioid overdoses in the united states, adolescents with OUD are far less likely than adults to receive and be retained on medication for opioid use disorder (MOUD). Estimates of timely MOUD initiation among adolescents with OUD are ≤ 5% and only a quarter of residential addiction treatment facilities for adolescents even offer buprenorphine. Among the few adolescents with OUD who do receive MOUD, adherence is alarmingly low. The multicomponent youth opioid recovery support (YORS) intervention for young adults seeks to increase adherence to extended-release MOUD and reduce opioid relapse through family involvement, assertive outreach, low-barrier access to MOUD, and contingency management. This project will expand the investigation of the YORS intervention, with demonstrated efficacy in young adults, to the critical underserved population of adolescents with OUD. Adolescents are theoretically even more likely than young adults to respond to YORS components such as family involvement, persuasion, and leverage because of their developmentally normative greater reliance on parental guidance and influence. Through this project we also will expand the YORS intervention to include adolescents with spanish-speaking family members and adolescents choosing sublingual buprenorphine, which are adaptations responsive to our local clinical experience and national trends. To achieve these aims, we will test the feasibility and pilot impact of YORS for N=40 adolescents and their family members in an uncontrolled, single arm clinical trial in preparation for a future larger scale randomized controlled trial. Second, we plan to adapt the YORS intervention to address health disparities in our community. Specifically, we will adapt YORS and its materials for spanish speakers, given our recent experience in usual clinical care, which has experienced an influx of spanish speaking adolescents using smoked fentanyl as pressed "percocet" pills. Third, because the preferred MOUD for adolescents in our clinical experience has been daily sublingual buprenorphine (rather than XR-MOUD), we will adapt YORS for sublingual buprenorphine. Finally, we will also conduct qualitative interviews to better understand the experience of adolescents with OUD and their families.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $576,675 | |
| Original award | $576,675 |
Quick answers
Who received award R34DA062260?
R34DA062260 was awarded to Maryland Treatment Centers, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 30, 2024.
How much is award R34DA062260 worth?
$1,153,350 has been obligated on R34DA062260.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award